Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies

NCT00255333 is registered in ClinicalTrials.gov with Innovive Pharmaceuticals as lead sponsor.

NCT NCT00255333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies
Lead sponsor
Innovive Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2005
Completion date
March 31, 2007
Enrollment
24
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tumors